- Consumers' cough-cold agenda influenced by retailers, suppliers
- Pfizer forms licensing agreement with Seattle Genetics
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Walgreens launches high-impact push in support of World AIDS Day campaign
- Hard to make cents out of pending FSA overhaul
NEWTON SQUARE, Pa. — Boiron on Thursday introduced a new pediatric cough-cold item to its lineup — Children’s Chestal Cold & Cough, a multi-symptom formula. The new syrup targets such symptoms of the common cold as nasal and chest congestion, cough, runny or stuffy nose, sneezing and minor sore throat. It provides parents with an option that works naturally with their little one’s bodies for children ages 3 years and older after manufacturers of antihistamines and decongestants relabeled their products for children 4 years of age and older.
Like Boiron’s other Chestal formula, this latest addition works to improve the productivity of all types of common coughs. The syrup coats and soothes little throats, and the blend of homeopathic medicines loosens chest congestion, thereby making common coughs more productive for a speedier recovery. This formula also targets a cough with thick phlegm associated with nasal congestion.
Additionally, Children’s Chestal Cold & Cough does not cause drowsiness or interact with other medications.
The most popular member of the Chestal all-star lineup is Children's Chestal 4.2 fl oz., Boiron reported. According to Boiron, over the 52-week period ending July 14, this SKU grew more than twice as much (14.5%) than the cough, cold and flu products category at the largest drug retailer (7.1%).